Pfizer unveils $214M biotech plant

Pfizer has opened a new, $214 million biotech manufacturing facility in Sweden. The 68,000-square-foot plant will make recombinant proteins based on e. coli and yeast as well as a branded human growth hormone. But Pfizer says that it built the plant to accommodate the production of a variety of therapies. Report

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”